1-18 of 18
James S. Wilmott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma

Tuba N. Gide, Yizhe Mao, Richard A. Scolyer, Georgina V. Long, James S. Wilmott
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5270–5280.
https://doi.org/10.1158/1078-0432.CCR-24-1109
Published: 02 December 2024
View article titled, Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma
Open the PDF for Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma in another window
Journal Articles

Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Hansol Lee, Angela L. Ferguson, Camelia Quek, Ismael A. Vergara, Ines Pires daSilva, Ruth Allen, Tuba Nur Gide, Jordan W. Conway, Lambros T. Koufariotis, Nicholas K. Hayward, Nicola Waddell, Matteo S. Carlino, Alexander M. Menzies, Robyn P.M. Saw, Elena Shklovskaya, Helen Rizos, Serigne Lo, Richard A. Scolyer, Georgina V. Long, Umaimainthan Palendira, James S. Wilmott
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2513–2524.
https://doi.org/10.1158/1078-0432.CCR-22-2657
Published: 05 July 2023
View article titled, Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Open the PDF for Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy in another window
Includes: Supplementary data
Journal Articles

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

James S. Wilmott, Hussein Tawbi, Johnathan A. Engh, Nduka M. Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saiag, Caroline Robert, Jean-Jacques Grob, Lisa H. Butterfield, Richard A. Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 521–531.
https://doi.org/10.1158/1078-0432.CCR-22-2581
Published: 01 February 2023
View article titled, Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Open the PDF for Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases in another window
Includes: Supplementary data
Journal Articles

Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Andrew W. Hahn, Ashley V. Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra, Tuba N. Gide, Camelia Quek, Yan Zang, Christine N. Spencer, Alexander M. Menzies, Carrie R. Daniel, Courtney W. Hudgens, Theodore Nowicki, Lauren E. Haydu, M.A. Wadud Khan, Vancheswaran Gopalakrishnan, Elizabeth M. Burton, Jared Malke, Julie M. Simon, Chantale Bernatchez, Nagireddy Putluri, Scott E. Woodman, Y.N. Vashisht Gopal, Renato Guerrieri, Grant M. Fischer, Jian Wang, Khalida M. Wani, John F. Thompson, Jeffrey E. Lee, Patrick Hwu, Nadim Ajami, Jeffrey E. Gershenwald, Georgina V. Long, Richard A. Scolyer, Michael T. Tetzlaff, Alexander J. Lazar, Dirk Schadendorf, Jennifer A. Wargo, John M. Kirkwood, Ralph J. DeBerardinis, Han Liang, Andrew Futreal, Jianhua Zhang, James S. Wilmott, Weiyi Peng, Michael A. Davies, Greg M. Delgoffe, Yana G. Najjar, Jennifer L. McQuade
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 154–164.
https://doi.org/10.1158/1078-0432.CCR-22-2661
Published: 04 January 2023
View article titled, Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Open the PDF for Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

Gregory M. Kelly, Fares Al-Ejeh, Robert McCuaig, Francesco Casciello, Nabilah Ahmad Kamal, Blake Ferguson, Antonia L. Pritchard, Sayed Ali, Ines P. Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Sudha Rao, Nicholas K. Hayward, Frank Gannon, Jason S. Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2624–2635.
https://doi.org/10.1158/1078-0432.CCR-20-3463
Published: 01 May 2021
View article titled, G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Open the PDF for G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma in another window
Includes: Supplementary data
Journal Articles

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Ailin Lepletier, Jason Madore, Jake S. O'Donnell, Rebecca L. Johnston, Xian-Yang Li, Elizabeth McDonald, Elizabeth Ahern, Anna Kuchel, Melissa Eastgate, Sally-Ann Pearson, Domenico Mallardo, Paolo A. Ascierto, Daniela Massi, Barbara Merelli, Mario Mandala, James S. Wilmott, Alexander M. Menzies, Charles Leduc, John Stagg, Bertrand Routy, Georgina V. Long, Richard A. Scolyer, Tobias Bald, Nicola Waddell, William C. Dougall, Michele W.L. Teng, Mark J. Smyth
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3671–3681.
https://doi.org/10.1158/1078-0432.CCR-19-3925
Published: 15 July 2020
View article titled, Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Open the PDF for Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Imran G. House, Peter Savas, Junyun Lai, Amanda X.Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (2): 487–504.
https://doi.org/10.1158/1078-0432.CCR-19-1868
Published: 15 January 2020
View article titled, Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Open the PDF for Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Novel Immune Targets in Melanoma—Response

Jarem Edwards, Marcel Batten, Angela Ferguson, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5424–5425.
https://doi.org/10.1158/1078-0432.CCR-19-1866
Published: 03 September 2019
View article titled, Novel Immune Targets in Melanoma—Response
Open the PDF for Novel Immune Targets in Melanoma—Response in another window
Journal Articles

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3247–3258.
https://doi.org/10.1158/1078-0432.CCR-18-4011
Published: 03 June 2019
View article titled, Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Open the PDF for Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Inês Pires da Silva, Kevin Y.X. Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John J. Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A. Scolyer, Jean Y.H. Yang, Georgina V. Long, Alexander M. Menzies
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1272–1279.
https://doi.org/10.1158/1078-0432.CCR-18-1680
Published: 15 February 2019
View article titled, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma
Open the PDF for Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

Jarem Edwards, James S. Wilmott, Jason Madore, Tuba Nur Gide, Camelia Quek, Annie Tasker, Angela Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Umaimainthan Palendira
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (13): 3036–3045.
https://doi.org/10.1158/1078-0432.CCR-17-2257
Published: 01 July 2018
View article titled, CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
Open the PDF for CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment in another window
Includes: Supplementary data
Journal Articles

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (6): 1260–1270.
https://doi.org/10.1158/1078-0432.CCR-17-2267
Published: 14 March 2018
View article titled, Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Open the PDF for Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

Hojabr Kakavand, Robert V. Rawson, Gulietta M. Pupo, Jean Y. H. Yang, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6054–6061.
https://doi.org/10.1158/1078-0432.CCR-16-1688
Published: 12 October 2017
View article titled, PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Open the PDF for PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma

Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Hojabr Kakavand, Jason Madore, Alexander Guminski, Elizabeth Liniker, Benjamin Y. Kong, Adam J. Cooper, Julie R. Howle, Robyn P.M. Saw, Valerie Jakrot, Serigne Lo, John F. Thompson, Matteo S. Carlino, Richard F. Kefford, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5024–5033.
https://doi.org/10.1158/1078-0432.CCR-16-0698
Published: 31 August 2017
View article titled, Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Open the PDF for Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma in another window
Includes: Supplementary data
Journal Articles

The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1

James S. Wilmott, Helen Rizos, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 2921–2923.
https://doi.org/10.1158/1078-0432.CCR-17-0669
Published: 14 June 2017
View article titled, The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1
Open the PDF for The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1 in another window
Journal Articles

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

Jason Madore, Dario Strbenac, Ricardo Vilain, Alexander M. Menzies, Jeen Y. H. Yang, John F. Thompson, Georgina V. Long, Graham J. Mann, Richard A. Scolyer, James S. Wilmott
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (15): 3915–3923.
https://doi.org/10.1158/1078-0432.CCR-15-1714
Published: 31 July 2016
View article titled, PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Open the PDF for PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3140–3148.
https://doi.org/10.1158/1078-0432.CCR-14-2023
Published: 14 July 2015
View article titled, PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Open the PDF for PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients in another window
Includes: Supplementary data
Journal Articles

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1386–1394.
https://doi.org/10.1158/1078-0432.CCR-11-2479
Published: 01 March 2012
View article titled, Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Open the PDF for Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma in another window
Includes: Supplementary data